Hongbo Lu - 15 Jun 2026 Form 4 Insider Report for Zenas BioPharma, Inc. (ZBIO)

Reporting relationship: Director
Issuer ticker: ZBIO
Reported as of: 15 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Jun 2026, 18:03:24 UTC
Prior SEC filing: 14 May 2026
Source filing: View source filing
Reporting owner signature: By: /s/ Jeffrey Held, Attorney-in-Fact

Key filing fact

Hongbo Lu filed Form 4 for Zenas BioPharma, Inc. (ZBIO) on 17 Jun 2026.

Key facts

This page summarizes Hongbo Lu's Form 4 filing for Zenas BioPharma, Inc. (ZBIO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 17 Jun 2026, 18:03.

Change

Previous filing in this sequence was filed on 14 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001767584 Primary reporting owner

Lu Hongbo

Relationship: Director
Address: C/O ZENAS BIOPHARMA, INC., 852 WINTER ST., SUITE 250, WALTHAM
Signature: By: /s/ Jeffrey Held, Attorney-in-Fact
Signature date: 17 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ZBIO transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +18,500
Change %
Price: $0.000000^*
Shares after: 18,500
Date: 15 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 18,500
Exercise price: $18.71
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests as to 100% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, subject to continued service.